NEW YORK (GenomeWeb) – Genomeon and Cloud Pharmaceuticals have signed an agreement to mine next-generation sequencing data to aid in drug development.

Under the terms of the agreement, Cloud Pharmaceuticals will be able to use Genomeon's microsatellite technology to find novel drug targets and companion biomarkers in NGS data.

Floyd, Virginia-based Genomeon analyzes short tandem repeat sequences, called microsatellites, which could serve as drug targets or biomarkers for diagnostic purposes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Seattle Times writes that pharmacogenomics testing can help choose medications that may work best for people with depression.

Researchers report that deleting one gene from butterflies affects their wing coloration patterns, according to the Washington Post.

In PNAS this week: genome sequencing of weevil symbionts, retinoid X receptor deletion in lung cancer metastasis, and more.

Sequencing could help combat foodborne illnesses, according to a blog post by Food and Drug Administration officials.